S&P 500   3,077.05 (-1.26%)
DOW   26,613.75 (-1.28%)
QQQ   212.45 (-1.86%)
AAPL   282.45 (-3.49%)
FB   193.50 (-1.88%)
MSFT   164.69 (-3.22%)
AMZN   1,941.61 (-1.92%)
CGC   19.27 (-2.78%)
NVDA   261.20 (-2.41%)
BABA   208.16 (-0.28%)
MU   51.87 (-0.95%)
GE   10.84 (-1.01%)
T   36.66 (-1.19%)
NFLX   386.14 (+1.82%)
DIS   121.99 (-1.11%)
GILD   74.36 (-0.46%)
S&P 500   3,077.05 (-1.26%)
DOW   26,613.75 (-1.28%)
QQQ   212.45 (-1.86%)
AAPL   282.45 (-3.49%)
FB   193.50 (-1.88%)
MSFT   164.69 (-3.22%)
AMZN   1,941.61 (-1.92%)
CGC   19.27 (-2.78%)
NVDA   261.20 (-2.41%)
BABA   208.16 (-0.28%)
MU   51.87 (-0.95%)
GE   10.84 (-1.01%)
T   36.66 (-1.19%)
NFLX   386.14 (+1.82%)
DIS   121.99 (-1.11%)
GILD   74.36 (-0.46%)
S&P 500   3,077.05 (-1.26%)
DOW   26,613.75 (-1.28%)
QQQ   212.45 (-1.86%)
AAPL   282.45 (-3.49%)
FB   193.50 (-1.88%)
MSFT   164.69 (-3.22%)
AMZN   1,941.61 (-1.92%)
CGC   19.27 (-2.78%)
NVDA   261.20 (-2.41%)
BABA   208.16 (-0.28%)
MU   51.87 (-0.95%)
GE   10.84 (-1.01%)
T   36.66 (-1.19%)
NFLX   386.14 (+1.82%)
DIS   121.99 (-1.11%)
GILD   74.36 (-0.46%)
S&P 500   3,077.05 (-1.26%)
DOW   26,613.75 (-1.28%)
QQQ   212.45 (-1.86%)
AAPL   282.45 (-3.49%)
FB   193.50 (-1.88%)
MSFT   164.69 (-3.22%)
AMZN   1,941.61 (-1.92%)
CGC   19.27 (-2.78%)
NVDA   261.20 (-2.41%)
BABA   208.16 (-0.28%)
MU   51.87 (-0.95%)
GE   10.84 (-1.01%)
T   36.66 (-1.19%)
NFLX   386.14 (+1.82%)
DIS   121.99 (-1.11%)
GILD   74.36 (-0.46%)
Log in

NASDAQ:INFI - Infinity Pharmaceuticals Stock Price, Forecast & News

$1.21
-0.05 (-3.97 %)
(As of 02/27/2020 12:30 PM ET)
Today's Range
$1.13
Now: $1.21
$1.22
50-Day Range
$1.07
MA: $1.32
$1.52
52-Week Range
$0.82
Now: $1.21
$1.95
Volume2,704 shs
Average Volume176,536 shs
Market Capitalization$69.01 million
P/E RatioN/A
Dividend YieldN/A
Beta1.75
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc to develop and commercialize products containing duvelisib in oncology indications., as well as collaboration agreements with Arcus Biosciences, Inc and Bristol-Myers Squibb Company. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INFI
CUSIP45665G30
Phone617-453-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.15 million
Book Value$0.92 per share

Profitability

Net Income$-11,250,000.00
Net Margins-1,519.91%

Miscellaneous

Employees25
Market Cap$69.01 million
Next Earnings Date3/3/2020 (Confirmed)
OptionableOptionable

Receive INFI News and Ratings via Email

Sign-up to receive the latest news and ratings for INFI and its competitors with MarketBeat's FREE daily newsletter.


Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) released its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.02. The biotechnology company earned $0.34 million during the quarter, compared to analyst estimates of $0.85 million. Infinity Pharmaceuticals had a negative return on equity of 125.37% and a negative net margin of 1,519.91%. View Infinity Pharmaceuticals' Earnings History.

When is Infinity Pharmaceuticals' next earnings date?

Infinity Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Infinity Pharmaceuticals.

How can I listen to Infinity Pharmaceuticals' earnings call?

Infinity Pharmaceuticals will be holding an earnings conference call on Tuesday, March 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for INFI?

3 analysts have issued 12 month price objectives for Infinity Pharmaceuticals' shares. Their forecasts range from $3.00 to $3.50. On average, they expect Infinity Pharmaceuticals' stock price to reach $3.25 in the next twelve months. This suggests a possible upside of 168.6% from the stock's current price. View Analyst Price Targets for Infinity Pharmaceuticals.

What is the consensus analysts' recommendation for Infinity Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Infinity Pharmaceuticals.

Has Infinity Pharmaceuticals been receiving favorable news coverage?

Press coverage about INFI stock has been trending negative on Thursday, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Infinity Pharmaceuticals earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Infinity Pharmaceuticals.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a decline in short interest in the month of February. As of February 14th, there was short interest totalling 48,300 shares, a decline of 61.2% from the January 30th total of 124,500 shares. Based on an average trading volume of 169,900 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.1% of the shares of the company are short sold. View Infinity Pharmaceuticals' Current Options Chain.

Who are some of Infinity Pharmaceuticals' key competitors?

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (Clr), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), ImmunoGen (IMGN), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Inovio Pharmaceuticals (INO) and Celldex Therapeutics (CLDX).

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the folowing people:
  • Ms. Adelene Q. Perkins, Chairman & CEO (Age 59)
  • Dr. Lawrence E. Bloch, Pres & Treasurer (Age 53)
  • Dr. Jeffery L. Kutok, Sr. VP & Chief Scientific Officer (Age 52)
  • Mr. Seth A. Tasker, VP, Gen. Counsel & Sec. (Age 40)
  • Ms. Melissa Hackel, VP of Fin.

Who are Infinity Pharmaceuticals' major shareholders?

Infinity Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.21%), Acadian Asset Management LLC (1.11%), Oxford Asset Management LLP (0.38%), Jacobs Levy Equity Management Inc. (0.24%) and Virtu Financial LLC (0.05%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Bvf Partners L P/Il, Jeffery Kutok and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.

Which major investors are selling Infinity Pharmaceuticals stock?

INFI stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for Infinity Pharmaceuticals.

Which major investors are buying Infinity Pharmaceuticals stock?

INFI stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Virtu Financial LLC and Acadian Asset Management LLC. Company insiders that have bought Infinity Pharmaceuticals stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Infinity Pharmaceuticals.

How do I buy shares of Infinity Pharmaceuticals?

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Infinity Pharmaceuticals' stock price today?

One share of INFI stock can currently be purchased for approximately $1.21.

How big of a company is Infinity Pharmaceuticals?

Infinity Pharmaceuticals has a market capitalization of $69.01 million and generates $22.15 million in revenue each year. The biotechnology company earns $-11,250,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis. Infinity Pharmaceuticals employs 25 workers across the globe.View Additional Information About Infinity Pharmaceuticals.

What is Infinity Pharmaceuticals' official website?

The official website for Infinity Pharmaceuticals is http://www.infi.com/.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]


MarketBeat Community Rating for Infinity Pharmaceuticals (NASDAQ INFI)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  342 (Vote Outperform)
Underperform Votes:  506 (Vote Underperform)
Total Votes:  848
MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe INFI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INFI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel